Shifalika Tangutoori
About Shifalika Tangutoori
Shifalika Tangutoori is a scientist specializing in drug delivery, currently working at SalioGen Therapeutics. She has extensive experience in lipid-based nanoparticle formulation and has held various academic and research positions, including postdoctoral roles at Harvard Medical School and Northeastern University.
Work at SalioGen Therapeutics
Shifalika Tangutoori currently serves as a Scientist in Drug Delivery at SalioGen Therapeutics, a position she has held since 2021. In this role, she focuses on developing innovative drug delivery systems, leveraging her extensive background in lipid-based nanoparticle formulation. Her work contributes to advancing therapeutic strategies within the organization.
Education and Expertise
Shifalika Tangutoori holds a Bachelor of Science in Pharmacy from Osmania University, which she completed from 2000 to 2004. She furthered her education at Northeastern University, where she earned both her Master of Science and Ph.D. in Pharmaceutical Sciences, specializing in drug delivery systems, from 2005 to 2010. Her academic background provides a strong foundation for her expertise in drug delivery and nanomedicine.
Background
Shifalika Tangutoori began her career in the field of pharmaceutical sciences with various roles in academia. She worked as a Tutor and Research Assistant at Illinois State University in 2005. Following this, she held several postdoctoral positions, including a Research Fellow at Harvard Medical School and a Research Associate in Nanomedicine at Northeastern University. She also served as a Visiting Scientist at the Dana Farber Cancer Institute.
Achievements
Shifalika Tangutoori is recognized for her contributions to the field of drug delivery, holding a patent as the primary inventor for a novel nano-liposomal drug application. She has developed novel in vitro assays for liposomes, focusing on their bio-distribution and therapeutic efficacy in mouse cancer models. Her research has been published in high-impact journals, highlighting its potential for clinical application.